Yungjin Pharm. Co., Ltd. (003520.KS)
KRW 1989.0
(-2.02%)
KRW 1989.0
(-2.02%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | -3.87 Billion KRW | 82.35% |
| 2022 | -21.96 Billion KRW | -89.61% |
| 2021 | -11.58 Billion KRW | -8600.68% |
| 2020 | -133.12 Million KRW | -102.65% |
| 2019 | 5.02 Billion KRW | 182.45% |
| 2018 | -6.1 Billion KRW | -426.65% |
| 2017 | 1.86 Billion KRW | -55.55% |
| 2016 | 4.2 Billion KRW | 24.09% |
| 2015 | 3.38 Billion KRW | 272.5% |
| 2014 | 909.09 Million KRW | -92.26% |
| 2013 | 11.74 Billion KRW | 554.45% |
| 2012 | 1.79 Billion KRW | -30.48% |
| 2011 | 2.58 Billion KRW | 211.79% |
| 2010 | -2.3 Billion KRW | 46.9% |
| 2009 | -4.34 Billion KRW | 35.43% |
| 2008 | -6.73 Billion KRW | 53.82% |
| 2007 | -14.58 Billion KRW | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q1 | 4.09 Billion KRW | 451.12% |
| 2024 Q2 | -1.45 Billion KRW | -135.58% |
| 2024 Q3 | -437 Million KRW | 69.99% |
| 2023 Q4 | -1.16 Billion KRW | -33.12% |
| 2023 Q1 | -154.11 Million KRW | 99.09% |
| 2023 Q2 | -1.68 Billion KRW | -990.28% |
| 2023 FY | -3.87 Billion KRW | 82.35% |
| 2023 Q3 | -875.57 Million KRW | 47.89% |
| 2022 Q3 | -2.09 Billion KRW | -48.26% |
| 2022 FY | -21.96 Billion KRW | -89.61% |
| 2022 Q1 | -1.45 Billion KRW | 14.91% |
| 2022 Q2 | -1.41 Billion KRW | 2.62% |
| 2022 Q4 | -16.99 Billion KRW | -709.98% |
| 2021 Q3 | -3.81 Billion KRW | 11.19% |
| 2021 Q4 | -1.7 Billion KRW | 55.17% |
| 2021 FY | -11.58 Billion KRW | -8600.68% |
| 2021 Q1 | -1.77 Billion KRW | 27.32% |
| 2021 Q2 | -4.29 Billion KRW | -141.85% |
| 2020 Q3 | -296.19 Million KRW | -138.96% |
| 2020 Q4 | -2.44 Billion KRW | -724.06% |
| 2020 FY | -133.12 Million KRW | -102.65% |
| 2020 Q1 | 1.84 Billion KRW | 160.99% |
| 2020 Q2 | 760.26 Million KRW | -58.76% |
| 2019 Q3 | 2.85 Billion KRW | -17.26% |
| 2019 FY | 5.02 Billion KRW | 182.45% |
| 2019 Q1 | 1.74 Billion KRW | 211.23% |
| 2019 Q2 | 3.45 Billion KRW | 97.8% |
| 2019 Q4 | -3.02 Billion KRW | -205.85% |
| 2018 Q2 | -2.15 Billion KRW | -725.77% |
| 2018 Q1 | 343.94 Million KRW | 126.22% |
| 2018 FY | -6.1 Billion KRW | -426.65% |
| 2018 Q4 | -1.56 Billion KRW | 42.4% |
| 2018 Q3 | -2.72 Billion KRW | -26.55% |
| 2017 Q4 | -1.31 Billion KRW | -295.81% |
| 2017 Q2 | 934.96 Million KRW | -40.63% |
| 2017 Q1 | 1.57 Billion KRW | 601.05% |
| 2017 Q3 | 669.97 Million KRW | -28.34% |
| 2017 FY | 1.86 Billion KRW | -55.55% |
| 2016 Q3 | 1.68 Billion KRW | -9.8% |
| 2016 Q4 | -314.27 Million KRW | -118.69% |
| 2016 FY | 4.2 Billion KRW | 24.09% |
| 2016 Q1 | 969.94 Million KRW | -28.36% |
| 2016 Q2 | 1.86 Billion KRW | 92.24% |
| 2015 Q2 | 165.73 Million KRW | -86.94% |
| 2015 Q4 | 1.35 Billion KRW | 126.43% |
| 2015 Q3 | 597.92 Million KRW | 260.77% |
| 2015 FY | 3.38 Billion KRW | 272.5% |
| 2015 Q1 | 1.26 Billion KRW | -12.38% |
| 2014 Q4 | 1.44 Billion KRW | 106.24% |
| 2014 Q3 | 702.08 Million KRW | 231.16% |
| 2014 Q2 | 212.01 Million KRW | 114.59% |
| 2014 Q1 | -1.45 Billion KRW | -131.6% |
| 2014 FY | 909.09 Million KRW | -92.26% |
| 2013 FY | 11.74 Billion KRW | 554.45% |
| 2013 Q3 | 1.6 Billion KRW | -56.54% |
| 2013 Q2 | 3.69 Billion KRW | 99.57% |
| 2013 Q1 | 1.84 Billion KRW | 33.66% |
| 2013 Q4 | 4.59 Billion KRW | 186.6% |
| 2012 FY | 1.79 Billion KRW | -30.48% |
| 2012 Q4 | 1.38 Billion KRW | -44.52% |
| 2012 Q3 | 2.49 Billion KRW | 128.44% |
| 2012 Q2 | 1.09 Billion KRW | 134.38% |
| 2012 Q1 | -3.17 Billion KRW | -982.17% |
| 2011 Q3 | 181.51 Million KRW | -64.9% |
| 2011 Q1 | 1.52 Billion KRW | 226.39% |
| 2011 Q4 | 359.93 Million KRW | 98.29% |
| 2011 Q2 | 517.19 Million KRW | -66.02% |
| 2011 FY | 2.58 Billion KRW | 211.79% |
| 2010 Q2 | 2.13 Billion KRW | 151.49% |
| 2010 Q1 | -4.14 Billion KRW | -1115.13% |
| 2010 Q4 | -1.2 Billion KRW | -232.82% |
| 2010 Q3 | 906.71 Million KRW | -57.52% |
| 2010 FY | -2.3 Billion KRW | 46.9% |
| 2009 FY | -4.34 Billion KRW | 35.43% |
| 2009 Q4 | -341.14 Million KRW | 62.91% |
| 2009 Q3 | -919.67 Million KRW | 57.45% |
| 2009 Q2 | -2.16 Billion KRW | -133.44% |
| 2009 Q1 | -925.83 Million KRW | 85.28% |
| 2008 Q3 | 181.71 Million KRW | 308.2% |
| 2008 Q4 | -6.28 Billion KRW | -3560.69% |
| 2008 Q2 | 44.51 Million KRW | 106.53% |
| 2008 FY | -6.73 Billion KRW | 53.82% |
| 2008 Q1 | -681.22 Million KRW | 78.27% |
| 2007 Q2 | -10.11 Billion KRW | -574.8% |
| 2007 Q3 | 169.67 Million KRW | 101.68% |
| 2007 Q1 | -1.49 Billion KRW | 0.0% |
| 2007 Q4 | -3.13 Billion KRW | -1947.52% |
| 2007 FY | -14.58 Billion KRW | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| Yuyu Pharma, Inc. | -7.18 Billion KRW | 46.03% |
| Dong-A Socio Holdings Co., Ltd. | 57.98 Billion KRW | 106.683% |
| Ildong Holdings Co., Ltd. | -59.58 Billion KRW | 93.496% |
| HANDOK Inc. | -28.79 Billion KRW | 86.542% |
| Kukje Pharma Co., Ltd. | -8.41 Billion KRW | 53.946% |
| Yuhan Corporation | 93.5 Billion KRW | 104.145% |
| Dong-A ST Co., Ltd. | 11.12 Billion KRW | 134.844% |
| SAMSUNG PHARM. Co., LTD. | -24.81 Billion KRW | 84.38% |
| Hanmi Pharm. Co., Ltd. | 146.23 Billion KRW | 102.65% |
| Hanall Biopharma Co.,Ltd | 3.5 Billion KRW | 210.458% |
| Ilyang Pharmaceutical Co.,Ltd | -2.5 Billion KRW | -54.625% |
| Dong Sung Bio Pharm.Co.,Ltd. | -2.07 Billion KRW | -86.871% |
| MYUNGMOON Pharm co.,Ltd | -4.52 Billion KRW | 14.35% |
| Hana Pharm Co., Ltd. | 22.33 Billion KRW | 117.354% |
| Yuyu Pharma, Inc. | -7.18 Billion KRW | 46.03% |
| Ilsung Pharmaceuticals Co., Ltd. | -20.94 Billion KRW | 81.493% |
| REYON Pharmaceutical Co., Ltd. | 3.58 Billion KRW | 208.153% |
| Aprogen pharmaceuticals,Inc. | -118.26 Billion KRW | 96.723% |
| JW Holdings Corporation | 19.02 Billion KRW | 120.369% |
| Ildong Pharmaceutical Co., Ltd. | -78.92 Billion KRW | 95.09% |
| Chong Kun Dang Pharmaceutical Corp. | 212.52 Billion KRW | 101.824% |
| JW Pharmaceutical Corporation | 37 Billion KRW | 110.473% |
| Shin Poong Pharm.Co.,Ltd. | -57.32 Billion KRW | 93.239% |
| Hyundai Pharmaceutical Co., Ltd. | 6.12 Billion KRW | 163.308% |
| Samil Pharmaceutical Co.,Ltd | 1.66 Billion KRW | 332.97% |
| Jeil Pharmaceutical Co.,Ltd | 5 Billion KRW | 177.437% |
| Yuyu Pharma, Inc. | -7.18 Billion KRW | 46.03% |
| Kwang Dong Pharmaceutical Co., Ltd. | 36.96 Billion KRW | 110.484% |
| Daewoong pharmaceutical Co.,Ltd | 111.5 Billion KRW | 103.476% |
| JW Pharmaceutical Corporation | 37 Billion KRW | 110.473% |
| Yuhan Corporation | 93.5 Billion KRW | 104.145% |
| Jeil Pharma Holdings Inc | -16.24 Billion KRW | 76.15% |
| Suheung Co., Ltd. | 6.11 Billion KRW | 163.334% |
| JW Pharmaceutical Corporation | 37 Billion KRW | 110.473% |
| Samjin Pharmaceuticals Co., Ltd. | 18.9 Billion KRW | 120.499% |
| Korea United Pharm Inc. | 48.26 Billion KRW | 108.03% |
| CKD Bio Corp. | -24.19 Billion KRW | 83.98% |
| Daewon Pharmaceutical Co., Ltd. | 23.91 Billion KRW | 116.204% |
| Dongwha Pharm.Co.,Ltd | 27.43 Billion KRW | 114.125% |
| Whan In Pharm Co.,Ltd. | 29.77 Billion KRW | 113.016% |
| Shin Poong Pharm.Co.,Ltd. | -57.32 Billion KRW | 93.239% |
| Chong Kun Dang Holdings Corp. | 47 Billion KRW | 108.245% |
| Boryung Corporation | 40.2 Billion KRW | 109.64% |
| Bukwang Pharmaceutical Co., Ltd. | -31.32 Billion KRW | 87.63% |
| Ilyang Pharmaceutical Co.,Ltd | -2.5 Billion KRW | -54.625% |
| JW Lifescience Corporation | 28.14 Billion KRW | 113.77% |